The company made this announcement after market hours on Friday, 7 October 2011.

Meanwhile, the BSE Sensex was up 223.27 points, or 1.38% to 16,455.81.

On BSE, 1,685 shares were traded in the counter as against an average daily volume of 17,134 shares in the past one quarter.

The stock hit a high of Rs 135.95 and a low of 133 so far during the day. The stock had hit a 52-week low of Rs 131.20 on 5 October 2011. The stock had hit a record high of Rs 269 crore on 20 December 2010.

The stock had underperformed the market over the past one month till 7 October 2011, declining 6.82% as compared to the Sensex's 4.88% fall. The scrip also underperformed the market in the past one quarter, falling 20.45% as compared to the Sensex's decline of 14.92%.

The company has an equity capital of Rs 18.06 crore. Face value per share is Rs 2.

Unichem Laboratories said Lamotrigine tablet is the generic version of GlaxoSmithKline's Lamictal. Lamotrigine is an anticonvulsant drug used in the treatment of epilepsy and for maintenance treatment of bipolar disorder.

Unichem Laboratories' net profit plunged 53.2% to Rs 15.62 crore on 0.1% rise in net sales to Rs 186.68 crore in Q1 June 2011 over Q1 June 2010.

Unichem Laboratories is an integrated specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world. In India, the company is a leader in niche therapy areas of cardiology, neurology, and orthopedics and anti-infectives. The company has strong skills in product development, process chemistry and manufacturing of complex active pharmaceutical ingredients (APIs) as well as dosage forms.